Obsidian Therapeutics director reports option holdings

Obsidian Therapeutics, Inc. director Matthew Norkunas reported his initial equity holdings.

Rhea-AI Filing Summary

Obsidian Therapeutics, Inc. director Matthew Norkunas reported his initial equity holdings. He holds stock options to acquire 180,000 shares of common stock at an exercise price of $0.7800 per share expiring May 24, 2033, and additional options over 51,563 shares at the same exercise price expiring June 24, 2034. These options vest in sixteen equal quarterly installments starting June 30, 2023 and June 25, 2024, respectively, subject to his continued service. He also directly holds 30,937 shares of common stock.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Norkunas Matthew

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy) F1	--	--	--
holding	Stock Option (Right to Buy) F2	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 231,563 contracts (Direct); Common Stock — 30,937 shares (Direct)

Footnotes (2)

1. F1. The shares underlying this option vest in sixteen (16) equal quarterly installments following June 30, 2023, subject to the Reporting Person's continued service on each such vesting date.
2. F2. The shares underlying this option vest in sixteen (16) equal quarterly installments following June 25, 2024, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Option underlying shares (2033 expiry): 180,000 shares Option underlying shares (2034 expiry): 51,563 shares Exercise price: $0.7800 per share +2 more

5 metrics

Option underlying shares (2033 expiry) 180,000 shares Stock Option (Right to Buy) expiring May 24, 2033

Option underlying shares (2034 expiry) 51,563 shares Stock Option (Right to Buy) expiring June 24, 2034

Exercise price $0.7800 per share Exercise price for both reported stock option grants

Direct common shares held 30,937 shares Directly held common stock following the reported holdings

Vesting installments 16 quarterly installments Each option grant vests in sixteen equal quarterly installments

Key Terms

Stock Option (Right to Buy), underlying security, vesting

3 terms

Stock Option (Right to Buy) financial

"security_title "Stock Option (Right to Buy)" with underlying common stock"

underlying security financial

"underlying_security_title "Common Stock" for each stock option grant"

vesting financial

"shares underlying this option vest in sixteen (16) equal quarterly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider position did Matthew Norkunas report at Obsidian Therapeutics (OBX)?

Matthew Norkunas, a director of Obsidian Therapeutics, reported initial holdings consisting of common stock and stock options to acquire additional common shares, all held directly.

How many Obsidian Therapeutics (OBX) options does Matthew Norkunas hold and at what exercise price?

He holds options over 180,000 and 51,563 shares of Obsidian Therapeutics common stock, each with an exercise price of $0.7800 per share, subject to vesting schedules.

When do Matthew Norkunas’s Obsidian Therapeutics (OBX) stock options expire?

His reported stock options expire on May 24, 2033 for 180,000 underlying shares and June 24, 2034 for 51,563 underlying shares of Obsidian Therapeutics common stock.

What is the vesting schedule for Matthew Norkunas’s Obsidian Therapeutics (OBX) options?

Each option grant vests in sixteen equal quarterly installments, one starting after June 30, 2023 and the other after June 25, 2024, contingent on his continued service on each vesting date.

How many Obsidian Therapeutics (OBX) common shares does Matthew Norkunas currently hold directly?

He directly holds 30,937 shares of Obsidian Therapeutics common stock, in addition to his unexercised stock options reported in the same disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/12/2026 - 07:10 PM Accepted by SEC EDGAR 08/03/2026 - 06:34 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Norkunas Matthew

(Last) (First) (Middle)

OBSIDIAN THERAPEUTICS, INC.

1030 MASSACHUSETTS AVE

(Street)

CAMBRIDGE MASSACHUSETTS 02138

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/03/2026

3. Issuer Name and Ticker or Trading Symbol
Obsidian Therapeutics, Inc. [ OBX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	30,937	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	05/24/2033	Common Stock	180,000	$0.78	D
Stock Option (Right to Buy)	(2)	06/24/2034	Common Stock	51,563	$0.78	D

Explanation of Responses:

1. The shares underlying this option vest in sixteen (16) equal quarterly installments following June 30, 2023, subject to the Reporting Person's continued service on each such vesting date.

2. The shares underlying this option vest in sixteen (16) equal quarterly installments following June 25, 2024, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Gabriela Morales-Rivera, Attorney-in-Fact	08/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)